Menu
Log in


Log in

MEMBER LOGIN

Targeting cell signaling in allergic asthma

Wed, October 16, 2024 1:08 PM | Anonymous

Asthma is chronic inflammation of the airways characterized by airway hyper-responsiveness, wheezing, cough, and dyspnea. Asthma affects >350 million people worldwide. The Th2 immune response is a major contributor to the pathophysiology of asthma. Targeted therapy modulating cell signaling pathways can be a powerful strategy to design new drugs to treat asthma. The potential molecular pathways that can be targeted include IL-4-IL-13-JAK-STAT-MAP kinases, adiponectin-iNOS-NF-κB, PGD2-CRTH2, IFNs-RIG, Wnt/β-catenin-FAM13A, FOXC1-miR-PI3K/AKT, JNK-Gal-7, Nrf2-ROS, Foxp3-RORγt, CysLTR, AMP, Fas-FasL, PTHrP/PPARγ, PAI-1, FcɛRI-LAT-SLP-76, Tim-3-Gal-9, TLRs-MyD88, PAR2, and Keap1/Nrf2/ARE. Therapeutic drugs can be designed to target one or more of these pathways to treat asthma

https://www.nature.com/articles/s41392-019-0079-0

CHICAGO ASTHMA CONSORTIUM
400 E. Randolph St., Suite 3115, Chicago, IL 60601
Phone: 888-268-8334 Fax: 312-540-9900

Information contained on this website is provided with the understanding that Chicago Asthma Consortium, this site and its services, including all of the resources provided, serve informational purposes only. Only a doctor who is treating you can provide you with medical advice, examination, diagnosis or treatment. If you think you may have a medical emergency, call your doctor or 911 immediately. The Chicago Asthma Consortium does not endorse any medical or professional services referred to on this site or any links to this site. It also does not recommend or endorse any specific tests, products, procedures, opinions, or any other information that may be mentioned. While we try to keep the information on this site accurate, we cannot guarantee its accuracy, timeliness or completeness.

© 2025 Chicago Asthma Consortium

Powered by Wild Apricot Membership Software